{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:49Z","timestamp":1786982749291,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["2020 Yeungnam University Research Grant"],"award-info":[{"award-number":["2020 Yeungnam University Research Grant"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40256-021-00516-3","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T20:02:25Z","timestamp":1639944145000},"page":"395-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Efficacy and Safety of Statin\u2013Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies"],"prefix":"10.1007","volume":"22","author":[{"given":"Kwang-Hee","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-6827","authenticated-orcid":false,"given":"Hye Duck","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1074248416686187","volume":"22","author":"DH Sherling","year":"2017","unstructured":"Sherling DH, Perumareddi P, Hennekens CH. Metabolic syndrome. J Cardiovasc Pharmacol Ther. 2017;22:365\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","volume":"46","author":"MR Taskinen","year":"2003","unstructured":"Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia. 2003;46:733\u20139.","journal-title":"Diabetologia"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227\u201339.","journal-title":"Circulation"},{"key":"516_CR4","doi-asserted-by":"publisher","unstructured":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486\u201397. https:\/\/doi.org\/10.1001\/jama.285.19.2486","DOI":"10.1001\/jama.285.19.2486"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet"},{"key":"516_CR6","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117\u201325.","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137:1571\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030950.","journal-title":"Circulation"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00129784-200303010-00007","volume":"3","author":"MJ Darkes","year":"2003","unstructured":"Darkes MJ, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs. 2003;3:67\u201376 (discussion 77\u20138).","journal-title":"Am J Cardiovasc Drugs"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"516_CR10","first-page":"445","volume":"113","author":"B Nubaumer","year":"2016","unstructured":"Nubaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-statin combination therapy. Dtsch Arztebl Int. 2016;113:445\u201353.","journal-title":"Dtsch Arztebl Int"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101\u201329.","journal-title":"Biometrics"},{"key":"516_CR13","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Henszel W. Statistical aspects of the analysis of data from retrospective sties of diseases. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Larid N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometircs. 1994;50:1088\u2013101.","journal-title":"Biometircs."},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1185\/030079904x2321","volume":"20","author":"L Simons","year":"2004","unstructured":"Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin. 2004;20:1437\u201345. https:\/\/doi.org\/10.1185\/030079904x2321.","journal-title":"Curr Med Res Opin"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1463-1326.2004.00420.x","volume":"7","author":"LM Gaudiani","year":"2005","unstructured":"Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005;7:88\u201397. https:\/\/doi.org\/10.1111\/j.1463-1326.2004.00420.x.","journal-title":"Diabetes Obes Metab"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3132\/dvdr.2006.020","volume":"3","author":"M Denke","year":"2006","unstructured":"Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc Dis Res. 2006;3:93\u2013102. https:\/\/doi.org\/10.3132\/dvdr.2006.020.","journal-title":"Diabetes Vasc Dis Res"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4065\/81.12.1579","volume":"81","author":"RB Goldberg","year":"2006","unstructured":"Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006;81:1579\u201388.","journal-title":"Mayo Clin Proc"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1463-1326.2007.00725.x","volume":"9","author":"C Constance","year":"2007","unstructured":"Constance C, Westphal S, Chung N, Lund M, Sisk CM, Johnson-Levonas AO, et al. Efficacy of ezetimibe\/simvastatin 10\/20 and 10\/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9:575\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/eurheartj\/ehn166","volume":"29","author":"M Settergren","year":"2008","unstructured":"Settergren M, B\u00f6hm F, Ryd\u00e9n L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycemia and coronary artery disease. Eur Heart J. 2008;29:1753\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehn166.","journal-title":"Eur Heart J"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/met.2009.0009","volume":"7","author":"AB Polis","year":"2009","unstructured":"Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Affiliations expand Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe\/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category. Metab Syndr Relat Disord. 2009;7:601\u201310. https:\/\/doi.org\/10.1089\/met.2009.0009.","journal-title":"Metab Syndr Relat Disord"},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-9-20","volume":"9","author":"G Bardini","year":"2010","unstructured":"Bardini G, Giorda CB, Pontiroli E, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010;9:20. https:\/\/doi.org\/10.1186\/1475-2840-9-20.","journal-title":"Cardiovasc Diabetol"},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2337\/dc10-0320","volume":"33","author":"P Ruggenenti","year":"2010","unstructured":"Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care. 2010;33:1954\u20136. https:\/\/doi.org\/10.2337\/dc10-0320.","journal-title":"Diabetes Care"},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1507\/endocrj.K10E-289","volume":"58","author":"Y Kawagoe","year":"2011","unstructured":"Kawagoe Y, Hattori Y, Nakano A, Aoki C, Tanaka S, Ohta S, et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J. 2011;58:171\u20135.","journal-title":"Endocr J"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2011.09.001","volume":"59","author":"Y Uemura","year":"2012","unstructured":"Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: Impact on the lipid profile in japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59:50\u20136.","journal-title":"J Cardiol"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1755-5922.2010.00181.x","volume":"30","author":"H Vaverkova","year":"2012","unstructured":"Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, et al. Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012;30:61\u201374. https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00181.x.","journal-title":"Cardiovasc Ther"},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-511X-12-103","volume":"12","author":"JB Rosen","year":"2013","unstructured":"Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, et al. Consistency of effect of ezetimibe\/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids Health Dis. 2013;12:103. https:\/\/doi.org\/10.1186\/1476-511X-12-103.","journal-title":"Lipids Health Dis"},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1476-511X-12-137","volume":"12","author":"K Torimoto","year":"2013","unstructured":"Torimoto K, Okada Y, Mori H, Hajime M, Tanaka K, Kurozumi A, et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12:137. https:\/\/doi.org\/10.1186\/1476-511X-12-137.","journal-title":"Lipids Health Dis"},{"key":"516_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/756294","volume":"2015","author":"G Villegas-Rivera","year":"2015","unstructured":"Villegas-Rivera G, Rom\u00e1n-Pintos LM, Cardona-Mu\u00f1oz EG, Arias-Carvajal O, Rodr\u00edguez-Carrizalez AD, Troyo-Sanrom\u00e1n R, et al. Effects of ezetimibe\/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid Med Cell Longev. 2015;2015: 756294. https:\/\/doi.org\/10.1155\/2015\/756294.","journal-title":"Oxid Med Cell Longev"},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12944-017-0508-4","volume":"16","author":"K Sakamoto","year":"2017","unstructured":"Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis. 2017;16:122\u20134. https:\/\/doi.org\/10.1186\/s12944-017-0508-4.","journal-title":"Lipids Health Dis"},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jcph.976","volume":"58","author":"MM El-Tamalawy","year":"2018","unstructured":"El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of combination therapy of ezetimibe and atorvastatin on remnant lipoprotein versus double atorvastatin dose in egyptian diabetic patients. J Clin Pharmacol. 2018;58:34\u201341. https:\/\/doi.org\/10.1002\/jcph.976.","journal-title":"J Clin Pharmacol"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00043798-199602000-00010","volume":"3","author":"A Menotti","year":"1996","unstructured":"Menotti A, Keys A, Blackburn H, Kromhout D, Karvonen M, Nissinen A, et al. Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J Cardiovasc risk. 1996;3:69\u201375.","journal-title":"J Cardiovasc risk"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1161\/01.CIR.103.17.2213","volume":"103","author":"AM Gotto Jr","year":"2001","unstructured":"Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103:2213\u20138.","journal-title":"Circulation"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.26355\/eurrev_201903_17279","volume":"23","author":"XY Miao","year":"2019","unstructured":"Miao XY, Liu HZ, Jin MM, Sun BR, Tian H, Li J, et al. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2019;23:2302\u201310. https:\/\/doi.org\/10.26355\/eurrev_201903_17279.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"516_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x]","volume":"13","author":"LA Leiter","year":"2011","unstructured":"Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe\/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011;13:615\u201328. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01383.x].","journal-title":"Diabetes Obes Metab"},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00125-006-0504-0","volume":"50","author":"SE Lally","year":"2007","unstructured":"Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and niemann-pick C1-like 1 mRNA. Diabetologia. 2007;50:217\u20139. https:\/\/doi.org\/10.1007\/s00125-006-0504-0.","journal-title":"Diabetologia"},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.metabol.2006.10.028","volume":"56","author":"S Lally","year":"2007","unstructured":"Lally S, Owens D, Tomkin GH. Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism. 2007;56:430\u20138.","journal-title":"Metabolism"},{"key":"516_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosissup.2008.05.012","volume":"9","author":"GH Tomkin","year":"2008","unstructured":"Tomkin GH. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler Suppl. 2008;9:27\u201332. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2008.05.012.","journal-title":"Atheroscler Suppl"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"T Kenichi","year":"2015","unstructured":"Kenichi T, Seigo S, Hitoshi S, Hideki S, Takuro Y, Kenshi Y, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065.","journal-title":"J Am Coll Cardiol"},{"key":"516_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5551\/jat.54726","volume":"28","author":"F Koichiro","year":"2021","unstructured":"Koichiro F, Kenshi Y, Suguru N, Hideki S, Takuro Y, Koichi N, et al. Effects of statin plus ezetimibe on coronary plaques in acute coronary syndrome patients with diabetes mellitus: sub-analysis of PRECISE-IVUS trial. J Atheroscler Thromb. 2021;28:181\u201393. https:\/\/doi.org\/10.5551\/jat.54726.","journal-title":"J Atheroscler Thromb"},{"key":"516_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12020-018-1541-4","volume":"60","author":"H Wu","year":"2018","unstructured":"Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018;60:229\u201339. https:\/\/doi.org\/10.1007\/s12020-018-1541-4.","journal-title":"Endocrine"},{"key":"516_CR44","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Cren AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6.","journal-title":"Lancet"},{"key":"516_CR45","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","volume":"57","author":"S Erqou","year":"2014","unstructured":"Erqou S, Lee CC, Adler AI. Statins and glycemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57:2444\u201352. https:\/\/doi.org\/10.1007\/s00125-014-3374-x.","journal-title":"Diabetologia"},{"key":"516_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.diabres.2009.10.008","volume":"87","author":"WL Baker","year":"2010","unstructured":"Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98\u2013107. https:\/\/doi.org\/10.1016\/j.diabres.2009.10.008.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00516-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:32:56Z","timestamp":1657240376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00516-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00516-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-605068\/v1","asserted-by":"object"}]},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"23 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by a 2020 Yeungnam University Research Grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Shin KH and Choi HD have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Shin KH and Choi HD conducted the search, collected the data, performed the analysis, and wrote the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}